scholarly journals Effects of inhaled salbutamol in exercising non-asthmatic athletes

Thorax ◽  
2001 ◽  
Vol 56 (9) ◽  
pp. 675-679
Author(s):  
C Goubault ◽  
M-C Perault ◽  
E Leleu ◽  
S Bouquet ◽  
P Legros ◽  
...  
Keyword(s):  
Endurance Performance ◽  
Cycle Ergometer ◽  
Metabolic Parameters ◽  
High Dose ◽  
Double Blind ◽  
Endurance Time ◽  
Post Exercise ◽  
Potassium Lactate ◽  
Exercise Induced ◽  
Inhaled Salbutamol

BACKGROUNDBeta-2 agonists such as salbutamol are used, not only by asthmatic athletes to prevent exercise induced asthma, but also by non-asthmatic athletes as a potentially ergogenic agent. We have investigated whether inhaled salbutamol enhances endurance performance in non-asthmatic athletes.METHODSA prospective double blind, randomised, three way crossover design was used to study the effects of 200 μg and 800 μg inhaled salbutamol versus a placebo in 12 trained triathletes. The treatments were compared in three identical cycle ergometer sessions at 85% of the predetermined maximal oxygen uptake. Lung function, endurance time, metabolic parameters (glucose, potassium, lactate, free fatty acid, and glycerol), and psychomotor performance were evaluated.RESULTSNeither endurance time nor post-exercise bronchodilation were significantly different between the treatments. Metabolic parameters were affected by exercise but not by treatment.CONCLUSIONSInhaled salbutamol, even in a high dose, did not have a significant effect on endurance performance in non-asthmatic athletes, although the bronchodilating effect of the drug at the beginning of exercise may have improved respiratory adaptation. Our results do not preclude an ergogenic effect of β2 agonists given by other routes or for a longer period.

Inhaled Terbutaline Administered via a Spacer Fully Prevents Exercise-Induced Asthma in Young Asthmatic Subjects: A Double-Blind, Randomized, Placebo-Controlled Study

1989 ◽  
Vol 17 (6) ◽  
pp. 506-513 ◽  
Author(s):  
A.T. Dinh Xuan ◽  
C. Lebeau ◽  
R. Roche ◽  
A. Ferriere ◽  
M. Chaussain
Keyword(s):  
Room Temperature ◽  
Work Load ◽  
Cycle Ergometer ◽  
Forced Expiratory Volume ◽  
Controlled Study ◽  
Adrenergic Agonist ◽  
Double Blind ◽  
Asthmatic Children ◽  
Exercise Induced ◽  
Age Range

The effects of inhaled terbutaline, a β2-adrenergic agonist, administered via a 750-ml spacer device were studied in young asthmatic subjects with exercise-induced asthma. A double-blind, randomized, placebo-controlled study of the effects of inhaled 0.5 mg terbutaline and placebo was conducted in 10 asthmatic children (age range 6–16 years) with documented exercise-induced asthma. Forced expiratory volume in 1 s (FEV1) was measured at baseline, 15 min after inhaling terbutaline or placebo, and at intervals up to 60 min after exercising. Subjects exercised using a cycle ergometer for 5 min at a submaximal, constant work-load while breathing dry air at room temperature. Terbutaline induced bronchodilation at rest in all subject and fully prevented exercise-induced asthma in nine out of the 10 subjects; the exercise-induced fall in FEV1 was markedly reduced in the remaining subject. It is concluded that exercise-induced asthma can be inhibited by pretreatment with inhaled terbutaline, administered via a spacer, in a majority of young asthmatics.

scholarly journals Adaptations to Post-exercise Cold Water Immersion: Friend, Foe, or Futile?

2021 ◽  
Vol 3 ◽  
Author(s):  
Mohammed Ihsan ◽  
Chris R. Abbiss ◽  
Robert Allan
Keyword(s):  
Exercise Performance ◽  
Cold Water ◽  
Water Immersion ◽  
Endurance Performance ◽  
Cold Water Immersion ◽  
Peroxisome Proliferator ◽  
Peroxisome Proliferator Activated Receptor ◽  
Post Exercise ◽  
Exercise Induced ◽  
Post Exercise Recovery

In the last decade, cold water immersion (CWI) has emerged as one of the most popular post-exercise recovery strategies utilized amongst athletes during training and competition. Following earlier research on the effects of CWI on the recovery of exercise performance and associated mechanisms, the recent focus has been on how CWI might influence adaptations to exercise. This line of enquiry stems from classical work demonstrating improved endurance and mitochondrial development in rodents exposed to repeated cold exposures. Moreover, there was strong rationale that CWI might enhance adaptations to exercise, given the discovery, and central role of peroxisome proliferator-activated receptor gamma coactivator-1α (PGC-1α) in both cold- and exercise-induced oxidative adaptations. Research on adaptations to post-exercise CWI have generally indicated a mode-dependant effect, where resistance training adaptations were diminished, whilst aerobic exercise performance seems unaffected but demonstrates premise for enhancement. However, the general suitability of CWI as a recovery modality has been the focus of considerable debate, primarily given the dampening effect on hypertrophy gains. In this mini-review, we highlight the key mechanisms surrounding CWI and endurance exercise adaptations, reiterating the potential for CWI to enhance endurance performance, with support from classical and contemporary works. This review also discusses the implications and insights (with regards to endurance and strength adaptations) gathered from recent studies examining the longer-term effects of CWI on training performance and recovery. Lastly, a periodized approach to recovery is proposed, where the use of CWI may be incorporated during competition or intensified training, whilst strategically avoiding periods following training focused on improving muscle strength or hypertrophy.

Abstract 617: Impact Of Pterostilbene On Blood Pressure and Other Metabolic Parameters In Adults

Hypertension ◽  
2012 ◽  
Vol 60 (suppl_1) ◽  
Author(s):  
Daniel M Riche ◽  
David Deschamp ◽  
Michael E Griswold ◽  
Corey L McEwen ◽  
Krista D Riche ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Reproductive Potential ◽  
Metabolic Parameters ◽  
Controlled Study ◽  
High Dose ◽  
Double Blind ◽  
Tract Disease ◽  
Cholesterol Therapy ◽  
Fibric Acids ◽  
Over Time

Objective: Pterostilbene is a polyphenol that is chemically related to resveratrol and commonly found in berries, such as blueberries. The purpose of this trial was to evaluate the effect of pterostilbene on metabolic parameters. METHODS: The trial was a prospective, randomized, double-blind, placebo-controlled study of patients with a total cholesterol ≥200 mg/dL and/or LDL ≥100 mg/dL. Patients were included if they were ≥18 years old and on either no cholesterol therapy or cholesterol medication at a stable dose for at least 2 months prior to baseline laboratory. Patients were excluded if they had significant hepatic, renal or GI tract disease or current overt cardiovascular disease; were receiving thiazolidinediones or fibric acids; were women who were pregnant or of reproductive potential. Eighty subjects were divided equally into one of four groups: (1) pterostilbene 125 mg twice daily; (2) pterostilbene 50 mg twice daily; (3) pterostilbene 50 mg + grape extract (GE) 100 mg twice daily; (4) matching placebo twice daily for 6-8 weeks. Patients received identical counseling on lifestyle intervention. Metabolic endpoints included blood pressure, body weight, and lipids. Linear mixed models were used to examine changes in metabolic parameters over time within treatment groups and compare changes over time across groups. Models were adjusted for age, sex and race. Results: The majority of patients completed the study (73/80; 91%). The average age was 54 years. The majority of patients were female (57/80; 71%), Caucasian (56/80; 70%), and had HTN (44/80; 55%). Both systolic (-7.8 mmHg; p<0.01) and diastolic blood pressure (-7.3 mmHg; p<0.001) were reduced with high dose pterostilbene. The only change in lipids was an increase in LDL with pterostilbene monotherapy (24.9 mg/dL; p<0.001) which was not seen with GE combination (p=0.47). Presence of a baseline cholesterol medication appeared to attenuate LDL effects. Patients not on cholesterol medication (n=51) exhibited minor weight loss with pterostilbene (-0.59 kg/m2; p=0.014). Conclusion: Pterostilbene reduces blood pressure in adults. Future studies should evaluate high dose pterostilbene with GE in a hypertensive population. Clinicaltrials.gov identifier NCT 01267227.

New Drug Evaluation Using Exercise-Induced Bronchospasm

PEDIATRICS ◽  
1975 ◽  
Vol 56 (5s) ◽  
pp. 937-939
Author(s):  
Arthur C. Sprenkle ◽  
Paul P. VanArsdel ◽  
C. Warren Bierman
Keyword(s):  
Oral Dose ◽  
Drug Evaluation ◽  
Clinical Effectiveness ◽  
Significant Inhibition ◽  
Optimal Dosage ◽  
Significant Activity ◽  
Double Blind ◽  
Post Exercise ◽  
Exercise Induced ◽  
Orally Active

Exercise-induced asthma was used to demonstrate that a xanthone, a new orally active cromolynlike drug, has significant activity in man. The effect of a single oral dose of 8 mg/kg was studied in a double-blind cross-over fashion at two and five hours after administration, with significant inhibition of post-exercise bronchopasm being seen at five hours. Further study seems indicated to determine optimal dosage and clinical effectiveness.

scholarly journals Pterostilbene on Metabolic Parameters: A Randomized, Double-Blind, and Placebo-Controlled Trial

2014 ◽  
Vol 2014 ◽  
pp. 1-8 ◽  
Author(s):  
Daniel M. Riche ◽  
Krista D. Riche ◽  
Chad T. Blackshear ◽  
Corey L. McEwen ◽  
Justin J. Sherman ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Weight Loss ◽  
Total Cholesterol ◽  
Mixed Models ◽  
Controlled Trial ◽  
Metabolic Parameters ◽  
Controlled Study ◽  
High Dose ◽  
Double Blind ◽  
Over Time

Introduction. The purpose of this trial was to evaluate the effect of pterostilbene on metabolic parameters.Methods. A prospective, randomized, double-blind, and placebo-controlled study that enrolled 80 patients with a total cholesterol ≥200 mg/dL and/orLDL≥100 mg/dL. Subjects were divided into four groups: (1) pterostilbene 125 mg twice daily; (2) pterostilbene 50 mg twice daily; (3) pterostilbene 50 mg + grape extract (GE) 100 mg twice daily; (4) matching placebo twice daily for 6–8 weeks. Endpoints included lipids, blood pressure, and weight. Linear mixed models were used to examine and compare changes in parameters over time. Models were adjusted for age, gender, and race.Results. LDL increased with pterostilbene monotherapy (17.1 mg/dL;P=0.001) which was not seen with GE combination (P=0.47). Presence of a baseline cholesterol medication appeared to attenuate LDL effects. Both systolic (−7.8 mmHg;P<0.01) and diastolic blood pressure (−7.3 mmHg;P<0.001) were reduced with high dose pterostilbene. Patients not on cholesterol medication (n=51) exhibited minor weight loss with pterostilbene (−0.62 kg/m2;P=0.012).Conclusion. Pterostilbene increases LDL and reduces blood pressure in adults. This trial is registered with Clinicaltrials.govNCT01267227.

scholarly journals Effects of 7-day supplementation with escalating doses of citrulline nitrate on resting and post-exercise blood pressure and safety biomarkers in healthy men: A randomized controlled trial

2021 ◽  
Vol 5 ◽  
pp. 239784732110386
Author(s):  
Nikola Todorovic ◽  
Valdemar Stajer ◽  
Laszlo Ratgeber ◽  
Jozsef Betlehem ◽  
Pongras Acs ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Controlled Trial ◽  
High Dose ◽  
Double Blind ◽  
Post Exercise ◽  
Hematological Indices ◽  
Healthy Men ◽  
Exercise Blood Pressure ◽  
Medium Dose ◽  
Apparently Healthy

We investigated the effects of 7-day supplementation with three different dosages of citrulline nitrate (CN) on blood pressure at rest and after exercise, biochemical safety markers, and self-reported outcome measures of adverse events in healthy men. 12 apparently healthy young men (age 25.9 ± 4.0 years; weight 78.6 ± 10.0 kg, height 181.0 ± 7.0 cm) volunteered to participate in this double-blind, randomized, placebo-controlled cross-over trial. The dosages of CN were 1.5 g per day (low dose), 3.0 g per day (medium dose), and 6.0 g per day (high dose). No significant differences were found for systolic and diastolic blood pressure and heart rate at rest and after exercise between varying doses of CN and placebo ( p > 0.05). In addition, hematological indices, biochemical variables, and clinical enzyme profiles were not affected by either intervention ( p > 0.05), and the type and frequency of side effects were comparable to the placebo group. Citrulline nitrate was safe and well tolerated when administered for 7 days in dosages up to 6 g per day.

scholarly journals Post-exercise urinary alpha-1 acid glycoprotein is not dependent on hypoxia

2021 ◽  
Author(s):  
Kelsey Elizabeth Joyce ◽  
George M. Balanos ◽  
Christopher Bradley ◽  
Amy Fountain ◽  
Arthur Randell Bradwell ◽  
...  
Keyword(s):  
Maximal Exercise ◽  
Cycle Ergometer ◽  
Performance Outcomes ◽  
Peak Power Output ◽  
Post Exercise ◽  
Acid Glycoprotein ◽  
The Difference ◽  
Exercise Induced ◽  
Physiologic Responses ◽  
Urine Specimens

Introduction: Proteinuria is a transient physiologic phenomenon that occurs with a range of physical activities and during ascent to altitude. Exercise intensity appears to dictate the magnitude of post-exercise proteinuria; however, evidence also indicates possible contributions from exercise-induced hypoxemia or reoxygenation. Utilizing an environmental hypoxic chamber, this crossover designed study aimed to evaluate urinary alpha-1 acid glycoprotein (α1-AGP) excretion pre/post exercise performed in hypoxia and normoxia. Methods: Sixteen individuals underwent experimental sessions in normoxia (NOR, 20.9% O2) and hypoxia (HYP, 12.0% O2). Sessions began with a 2-hour priming period before completing a graded maximal exercise test (GXT) on a cycle ergometer, which was followed by continuation of exposure for an additional 2 hours. Physiologic responses (i.e., blood pressure, heart rate, and peripheral oxygenation), Lake Louise Scores, and urine specimens (analyzed for albumin and α1-AGP) were collected pre- and post-exercise (after 30, 60, and 120 minutes). Results: Peak power output was significantly reduced in HYP (193 ± 45 W) compared to NOR (249 ± 59 W, p < 0.01). Post-exercise urinary α1-AGP was greater in NOR (20.04 ± 14.84 μg•min-1) compared to HYP (15.08 ± 13.46 μg•min-1), albeit the difference was not significant (p > 0.05). Changes in urinary α1-AGP from pre- to post-30 minutes were not related to physiologic responses or performance outcomes observed during GXT in NOR or HYP. Conclusion: Despite profound systemic hypoxemia with maximal exercise in hypoxia, post-exercise α1-AGP excretion was not elevated above levels observed following normoxic exercise.

Double-Blind Study of Inhaled Salbutamol Versus Salbutamol Plus High-Dose Flunisolide in Exacerbation of Bronchial Asthma: A Pilot Study

1997 ◽  
Vol 11 (1) ◽  
pp. 23-30 ◽  
Author(s):  
MARIO LA ROSA ◽  
CARMELA RANNO ◽  
GIUSEPPA MANDARÀ ◽  
ANGELO BARBATO ◽  
MAURIZIO BIRAGHI
Keyword(s):  
Pilot Study ◽  
Bronchial Asthma ◽  
Blind Study ◽  
High Dose ◽  
Double Blind Study ◽  
Double Blind ◽  
Inhaled Salbutamol

scholarly journals Cyclooxygenase inhibitors and the exercise-induced stress response

2006 ◽  
Vol 18 (1) ◽  
pp. 4 ◽  
Author(s):  
N Claassen ◽  
J Snyman ◽  
A Koorts ◽  
H Nolte ◽  
B Wagenaar ◽  
...  
Keyword(s):  
Single Dose ◽  
Stress Response ◽  
Sports Medicine ◽  
Temperature Response ◽  
Cyclooxygenase Inhibitors ◽  
Double Blind ◽  
Post Exercise ◽  
Induced Stress ◽  
Cyclooxygenase 1 ◽  
Exercise Induced

Objective. This study investigated the effects of single dosages of the non-steroidal anti-inflammatory drug (NSAID) naproxen, and of the coxib, rofecoxib, on the exercise-induced stress response. Design. Eight subjects (age 20.9 ± 1.1 years, weight 70.4 ± 3.9 kg, height 170.9 ± 6.7 cm, body surface area 1.82 ± 0.09 m2, body mass index 24.1 ± 1.3 kg.m-2) took part in a double-blind, drug-placebo, cross-over design study. The experimental procedures were performed on 3 occasions on each volunteer, i.e. once on placebo, once on naproxen (single dose of 1 000 mg) and once on rofecoxib (single dose of 50 mg). Results. Mean post-exercise cortisol values were significantly higher than pre-exercise values with the subjects on placebo (p = 0.0365) and rofecoxib (p = 0.0208), but not on naproxen (p = 0.0732). Post-exercise oral temperatures were significantly higher than pre-exercise temperature values on placebo (p = 0.0153) and rofecoxib (p = 0.0424), but not on naproxen (p = 0.5444). Conclusion. The results of this study suggest a role for cyclooxygenase-1 (COX-1) in the exercise-induced cortisol and temperature response to exercise. South African Journal of Sports Medicine Vol. 18 (1) 2006: pp. 4-8

scholarly journals Cyclooxygenase inhibitors and the exercise-induced stress response

2009 ◽  
Vol 18 (1) ◽  
pp. 4
Author(s):  
N Claassen ◽  
J Snyman ◽  
A Koorts ◽  
H Nolte ◽  
B Wagenaar ◽  
...  
Keyword(s):  
Single Dose ◽  
Stress Response ◽  
Sports Medicine ◽  
Temperature Response ◽  
Cyclooxygenase Inhibitors ◽  
Double Blind ◽  
Post Exercise ◽  
Induced Stress ◽  
Cyclooxygenase 1 ◽  
Exercise Induced

Objective. This study investigated the effects of single dosages of the non-steroidal anti-inflammatory drug (NSAID) naproxen, and of the coxib, rofecoxib, on the exercise-induced stress response. Design. Eight subjects (age 20.9 ± 1.1 years, weight 70.4 ± 3.9 kg, height 170.9 ± 6.7 cm, body surface area 1.82 ± 0.09 m2, body mass index 24.1 ± 1.3 kg.m-2) took part in a double-blind, drug-placebo, cross-over design study. The experimental procedures were performed on 3 occasions on each volunteer, i.e. once on placebo, once on naproxen (single dose of 1 000 mg) and once on rofecoxib (single dose of 50 mg). Results. Mean post-exercise cortisol values were significantly higher than pre-exercise values with the subjects on placebo (p = 0.0365) and rofecoxib (p = 0.0208), but not on naproxen (p = 0.0732). Post-exercise oral temperatures were significantly higher than pre-exercise temperature values on placebo (p = 0.0153) and rofecoxib (p = 0.0424), but not on naproxen (p = 0.5444). Conclusion. The results of this study suggest a role for cyclooxygenase-1 (COX-1) in the exercise-induced cortisol and temperature response to exercise. South African Journal of Sports Medicine Vol. 18 (1) 2006: pp. 4-8

Sign in / Sign up

Export Citation Format

Share Document